[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-354312-105":59,"doc-detail-354312-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","repurposing-rilmenidine-as-a-potential-antimetastatic-therapy-targeting-nischarin-in-pancreatic-ductal-adenocarcinoma","Repurposing Rilmenidine as a Potential Antimetastatic Therapy Targeting Nischarin in Pancreatic Ductal Adenocarcinoma","","Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive cancer with early metastatic spread and a dense desmoplastic stroma that reduce therapeutic effectiveness. Nischarin (NISCH)/imidazoline-1 receptor (IR-1) functions as a potential tumor suppressor involved in migration, invasion, and cytoskeletal organization, and clinically approved agonists can target this receptor. This study evaluates NISCH in PDAC, tests three NISCH agonists, and examines drug effects in vitro, in coculture with cancer-associated fibroblasts, and in an in vivo zebrafish xenograft model. Rilmenidine decreases viability at high doses, induces apoptosis, reduces adhesion and migration, dampens CAF activation markers and cytokine communication, and limits metastatic spread. Results support rilmenidine as a promising drug-repurposing antimetastatic candidate and validate NISCH as a target for new PDAC therapeutics.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/repurposing-rilmenidine-as-a-potential-antimetastatic-therapy-targeting-nischarin-in-pancreatic-ductal-adenocarcinoma/354312/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/repurposing-rilmenidine-as-a-potential-antimetastatic-therapy-targeting-nischarin-in-pancreatic-ductal-adenocarcinoma/354312.png","ImageObject",300,407,{"name":92,"@type":93},"McGucket","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-23","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":52},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What role does Nischarin (NISCH)/IR-1 play in pancreatic ductal adenocarcinoma?","Question",{"text":112,"@type":113},"NISCH/IR-1 is described as a potential tumor suppressor involved in regulating cell migration, invasion, and cytoskeletal organization, which are critical processes in PDAC progression.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How does rilmenidine affect PDAC cells compared with other NISCH agonists?",{"text":117,"@type":113},"Among moxonidine, clonidine, and rilmenidine, rilmenidine uniquely affected cancer cell viability and, at high doses, induced apoptosis.",{"name":119,"@type":110,"acceptedAnswer":120},"What evidence supports rilmenidine as an antimetastatic drug candidate?",{"text":121,"@type":113},"Rilmenidine treatment reduced adhesion and migration in vitro, decreased CAF activation markers and cancer cell–CAF cytokine communication in coculture, and limited metastatic spread in an in vivo tumor xenograft zebrafish model.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},354312,1790535925,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":52,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},1236954412713,"https://us-avatar.wpscdn.com/davatar_29158cc5080c5b710cf443261637dec0","Article  \nRepurposing Rilmenidine as a Potential Antimetastatic Therapy Targeting Nischarin in Pancreatic Ductal Adenocarcinoma  \nKristina Živi´c 1, Marijana Pavlovi´c 1, Marija Ostoji´c 1, Danijel Galun 2,3, Aleksandar Pavi´c 4, Tatjana Srdi´c-Raji´c 1 and Jelena Grahovac 1, *  \nAcademic Editor: Carmine Stolfi and Federica Laudisi  \nReceived: 14 May 2026  \nRevised: 27 May 2026  \nAccepted: 1 June 2026  \nPublished: 3 June 2026  \nCopyright: © 2026 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license.  \n1 Department of Experimental Oncology, Institute for Oncology and Radiology of Serbia, 11000 Belgrade, Serbia  \n2 School of Medicine, University of Belgrade, 11000 Belgrade, Serbia  \n3 HPB Unit, Clinic for Digestive Surgery, University Clinical Center of Serbia, 11000 Belgrade, Serbia  \n4 Institute of Molecular Genetics and Genetic Engineering, University of Belgrade, 11000 Belgrade, Serbia  \n* [Correspondence: jelena.grahovac@ncrc.ac.rs](Correspondence: jelena.grahovac@ncrc.ac.rs)  \nAbstract  \nPancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive cancer types with a dismal prognosis, where early metastatic dissemination and rich desmoplasticstroma limit the therapeutic efficacy. Nischarin (NISCH)/Imidazoline-1 receptor (IR-1) is a potential tumor suppressor that is involved in the regulation of cell migration, invasion, and cytoskeletal organization. Importantly, several clinically approved agonists have been shown to target this receptor. This study aimed to examine NISCH expression in PDAC and the effects of its agonists with the intent of drug repurposing. NISCH was expressed in PDAC tumor tissue, in both the epithelial and stromal compartments of tumors, and higher NISCH expression was associated with longer patient survival. Out of the three tested NISCH agonists, moxonidine, clonidine and rilmenidine, rilmenidine was the only one affecting cancer cell viability and at high doses induced cancer cell apoptosis. Transcriptome analysis of rilmenidine-treated PDAC cells revealed changes associated with cytoskeletal organization, translating into decreased adhesion and migration in vitro. In cancer-associated fibroblasts (CAFs), rilmenidine treatment decreased the expression of activation markers and limited cancer cell-CAF cytokine communication in the coculture. Ultimately, in the in vivo tumor xenograft zebrafish model, rilmenidine reduced the metastatic spread of pancreatic cancer cells. Our results suggest that the NISCH agonist rilmenidine is a promising candidate for drug repurposing as an antimetastatic agent in PDAC, and that NISCH can be a potential target for the development of new PDAC therapeutics.  \nKeywords: pancreatic cancer; nischarin; rilmenidine; drug repurposing; metastasis  \n1. Introduction  \nPancreatic cancer is one of the most lethal cancers, with a five-year survival rate of 13%[1] . Pancreatic ductal adenocarcinoma (PDAC) accounts for almost 90% of all pancreatic cancer cases [2] . With clinically silent early lesions, PDAC is generally diagnosed at an already advanced stage when it has metastasized to other organs, and the treatment options are limited [3] . Only 20% of PDAC patients are amenable to potentially curable surgical removal [4] . Unfortunately, even in patients with upfront resection and adjuvant therapy, the five-year survival rate that can be expected is only 19%[5] . Metastatic dissemination in PDAC starts very early [6], and it is estimated that only five years are required for the initial  \nnon-metastatic founder cell to acquire the metastatic ability [7] . Despite improvements in therapeutic approaches, PDAC remains poorly responsive to chemotherapy, targeted therapy, and immunotherapies, and currently, there are no specific approaches for targeting the metastatic disease.  \nFibrosis is the main feature of PDAC, and the dense stroma—consisti","cbCaigUHd6T7aIZT","https://ap.wps.com/l/cbCaigUHd6T7aIZT","pdf",14074511,27,"English","# Abstract\n# Introduction","[{\"question\":\"What role does Nischarin (NISCH)/IR-1 play in pancreatic ductal adenocarcinoma?\",\"answer\":\"NISCH/IR-1 is described as a potential tumor suppressor involved in regulating cell migration, invasion, and cytoskeletal organization, which are critical processes in PDAC progression.\"},{\"question\":\"How does rilmenidine affect PDAC cells compared with other NISCH agonists?\",\"answer\":\"Among moxonidine, clonidine, and rilmenidine, rilmenidine uniquely affected cancer cell viability and, at high doses, induced apoptosis.\"},{\"question\":\"What evidence supports rilmenidine as an antimetastatic drug candidate?\",\"answer\":\"Rilmenidine treatment reduced adhesion and migration in vitro, decreased CAF activation markers and cancer cell–CAF cytokine communication in coculture, and limited metastatic spread in an in vivo tumor xenograft zebrafish model.\"}]","Repurposing Rilmenidine as a Potential Antimetastatic Therapy Targeting Nischarin in Pancreatic Ductal Adenocarcinoma | PDF",1790110024,68,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0a3c3c6fd266469666f183b60f4eaf65.webp",983,1390,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7e889836c2d58927f37ee9ece6c3e0f3.webp",982,1388,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/52fc0092b352b44972ebb884303d4b65.webp",981,1387,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e93eb833b9af39121b8fc8d153047b37.webp",980,1385]